Prescription drug · BLA
Mvasi (Bevacizumab-awwb) NDC 55513-206
Bevacizumab 100 mg/4mL · Injection, Solution · Intravenous · Amgen, Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 55513-206-01 | 5551302060155513020601 | 1 VIAL in 1 CARTON (55513-206-01) / 4 mL in 1 VIALMarketed from Jun 1, 2018 | |
| 55513-206-21 | 5551302062155513020621 | 1 VIAL in 1 CARTON (55513-206-21) / 4 mL in 1 VIALMarketed from Jun 27, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Mvasi
- Generic name (nonproprietary)
- bevacizumab-awwb
- Active ingredients
- Bevacizumab — 100 mg/4mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Amgen, IncNDC labeler code 55513
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761028
- Marketing start
- Listing expires
- Other FDA classes
- Vascular Endothelial Growth Factor Inhibitors (Mechanism)Vascular Endothelial Growth Factor-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 55513-206_ea079b8e-24b7-4e03-8340-8078f30f6d98SPL ID ea079b8e-24b7-4e03-8340-8078f30f6d98SPL set ID 0a562b4e-67ce-4bab-852c-d9ee71e55fb8RxCUI 2046140, 2046145, 2046148, 2046149UNII 2S9ZZM9Q9V
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J9035 — Injection, bevacizumab, 10 mg
Billing unit: 10 mg. Units on the claim = dose given ÷ 10 mg.
Bevacizumab biosimilars have their own HCPCS codes.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N455513020601followed by a unit qualifier and the quantityPackage 55513-0206-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin …
Excerpt only. Read the full label for complete information.
About NDC 55513-206
- What is NDC 55513-206?
- 55513-206 is the product NDC for Mvasi (bevacizumab-awwb), Bevacizumab 100 mg/4mL injection, solution, listed with the FDA by Amgen, Inc. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Mvasi (Bevacizumab-awwb).
- What is the active ingredient?
- Bevacizumab.
- Who is the labeler?
- Amgen, Inc, NDC labeler code 55513. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Mvasi?
- 1 other product NDC are listed under this name. See all Mvasi NDCs.
- Is there a related HCPCS / J-code?
- Yes: J9035, Injection, bevacizumab, 10 mg. See Billing references above.
Related NDCs: other Mvasi products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Mvasibevacizumab-awwb | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Amgen, Inc | 55513-207 | 55513-0207-0155513-0207-21 |
Other NDCs under BLA 761028
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Mvasibevacizumab-awwb | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Amgen, Inc | 55513-207 |